Congress Events
This section features selected RRD abstracts, posters, and presentations that have been presented at medical or scientific congresses. This content is subject to the copyright and other use restrictions noted on the applicable material permissions. Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. RRD does not suggest or recommend the use of RRD products in any manner other than as described in the Prescribing Information. Any third- party information provided represents the point of view of the authors and not the opinion of RRD.
Please be aware that any information included in Congress materials regarding pipeline products under development or investigational uses does not imply FDA approval for these products or uses, nor does it establish their safety or efficacy. There is no guarantee that pipeline products or investigational uses will receive FDA approval.
Oncology
Idiopathic Multicentric Castleman Disease
Burden of idiopathic multicentric Castleman disease in the US: a population-level real world analysis using a health-claims dataset.
Noy A, Ohgami R, Munshi N, et al.
Presented at American Society of Hematology; December 7-10, 2024; San Diego, CA.
Siltuximab
Prescribing InformationBurden of idiopathic multicentric Castleman disease in the US: a population-level real world analysis using a health-claims dataset.
Noy A, Ohgami R, Munshi N, et al.
Presented at American Society of Hematology; December 7-10, 2024; San Diego, CA.
Hematology
Cold Agglutinin Disease
Baseline characteristics from the first interim analysis of CADENCE, the cold agglutinin disease (CAD)/cold agglutinin syndrome (CAS) registry.
Michel M, Barcellini W, Broome CM, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Cumulative effect of abnormal biomarkers on the risk of mortality and thromboembolic events in patients with cold agglutinin disease.
Hill QA, Roth A, Barcellini W, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Efficacy of sutimlimab stratified by baseline hemoglobin in patients with cold agglutinin disease: a post hoc analysis from CARDINAL and CADENZA.
Roth A, Broome CM, Barcellini W, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Fatigue severity thresholds in cold agglutinin disease: post-hoc analyses on the FACIT-Fatigue scale from two Phase 3 trials.
Cella D, Weitz I, Ueda Y, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Sutimlimab in patients with cold agglutinin disease with prior rituximab use versus rituximab-naïve patients: post-hoc analyses from Phase 3 studies.
Roth A, Karaouni A, Hemim I, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Combined safety data for sutimlimab in cold agglutinin disease: a post hoc analysis of the phase 3 CARDINAL and CADENZA studies.
Broome CM, Barcellini W, Ueda Y, et al.
Presented at American Society of Hematology; December 9-12, 2023; San Diego, CA.
Thromboembolic (TE) events in cold agglutinin disease (CAD): post hoc analysis PRE- and ON-sutimlimab treatment in the Phase 3 CARDINAL and CADENZA studies.
Roth A, Ueda Y, McCrae K, et al.
Presented at International Society on Thrombosis and Haemostasis; June 24-28, 2023; Montreal, Quebec,
Canada.
Concomitant use of sutimlimab and COVID-19 vaccines in patients with cold agglutinin disease from the Phase 3 CARDINAL and CADENZA studies.
Fattizzo B, Roth A, Broome CM, et al.
Presented at European Hematology Association; June 8-11, 2023; Frankfurt, Germany.
Hemolytic markers, mortality, and thromboembolic events in CAD: risk assessment by time period since diagnosis.
Hill QA, Barcellini W, Roth A, et al.
Presented at European Hematology Association; June 8-11, 2023; Frankfurt, Germany.
Serum biomarkers as predictors of response to sutimlimab in cold agglutinin disease (CAD): a post-hoc analysis of Phase 3 CARDINAL and CADENZA study data.
Barcellini W, Broome CM, Jilma B, et al.
Presented at European Hematology Association; June 8-11, 2023; Frankfurt, Germany.
Hemolytic markers, mortality, and thromboembolic events in cold agglutinin disease (CAD): a retrospective analysis of the Optum® de identified electronic health record dataset in the United States.
Broome C, Barcellini W, Roth A, et al.
Presented at American Society of Hematology; December 10-13, 2022; New Orleans, LA.
Seasonality of healthcare resource utilization among cold agglutinin disease patients in Denmark: a retrospective analysis.
Fryzek J, Hooda N, Esen B, et al.
Presented at European Hematology Association; June 9-12, 2022; Vienna, Austria.
Sutimlimab after prior rituximab use in patients with cold agglutinin disease (CAD): pooled post-hoc analysis from the CARDINAL and CADENZA trials.
Roth A, Karaouni A, Msihid J, et al.
Presented at European Hematology Association; June 9-12, 2022; Vienna, Austria.
Sutimlimab-jome
Prescribing InformationBaseline characteristics from the first interim analysis of CADENCE, the cold agglutinin disease (CAD)/cold agglutinin syndrome (CAS) registry.
Michel M, Barcellini W, Broome CM, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Cumulative effect of abnormal biomarkers on the risk of mortality and thromboembolic events in patients with cold agglutinin disease.
Hill QA, Roth A, Barcellini W, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Efficacy of sutimlimab stratified by baseline hemoglobin in patients with cold agglutinin disease: a post hoc analysis from CARDINAL and CADENZA.
Roth A, Broome CM, Barcellini W, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Fatigue severity thresholds in cold agglutinin disease: post-hoc analyses on the FACIT-Fatigue scale from two Phase 3 trials.
Cella D, Weitz I, Ueda Y, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Sutimlimab in patients with cold agglutinin disease with prior rituximab use versus rituximab-naïve patients: post-hoc analyses from Phase 3 studies.
Roth A, Karaouni A, Hemim I, et al.
Presented at European Hematology Association; June 13-16, 2024; Madrid, Spain.
Combined safety data for sutimlimab in cold agglutinin disease: a post hoc analysis of the phase 3 CARDINAL and CADENZA studies.
Broome CM, Barcellini W, Ueda Y, et al.
Presented at American Society of Hematology; December 9-12, 2023; San Diego, CA.
Thromboembolic (TE) events in cold agglutinin disease (CAD): post hoc analysis PRE- and ON-sutimlimab treatment in the Phase 3 CARDINAL and CADENZA studies.
Roth A, Ueda Y, McCrae K, et al.
Presented at International Society on Thrombosis and Haemostasis; June 24-28, 2023; Montreal, Quebec,
Canada.
Concomitant use of sutimlimab and COVID-19 vaccines in patients with cold agglutinin disease from the Phase 3 CARDINAL and CADENZA studies.
Fattizzo B, Roth A, Broome CM, et al.
Presented at European Hematology Association; June 8-11, 2023; Frankfurt, Germany.
Hemolytic markers, mortality, and thromboembolic events in CAD: risk assessment by time period since diagnosis.
Hill QA, Barcellini W, Roth A, et al.
Presented at European Hematology Association; June 8-11, 2023; Frankfurt, Germany.
Serum biomarkers as predictors of response to sutimlimab in cold agglutinin disease (CAD): a post-hoc analysis of Phase 3 CARDINAL and CADENZA study data.
Barcellini W, Broome CM, Jilma B, et al.
Presented at European Hematology Association; June 8-11, 2023; Frankfurt, Germany.
Hemolytic markers, mortality, and thromboembolic events in cold agglutinin disease (CAD): a retrospective analysis of the Optum® de identified electronic health record dataset in the United States.
Broome C, Barcellini W, Roth A, et al.
Presented at American Society of Hematology; December 10-13, 2022; New Orleans, LA.
Seasonality of healthcare resource utilization among cold agglutinin disease patients in Denmark: a retrospective analysis.
Fryzek J, Hooda N, Esen B, et al.
Presented at European Hematology Association; June 9-12, 2022; Vienna, Austria.
Sutimlimab after prior rituximab use in patients with cold agglutinin disease (CAD): pooled post-hoc analysis from the CARDINAL and CADENZA trials.
Roth A, Karaouni A, Msihid J, et al.
Presented at European Hematology Association; June 9-12, 2022; Vienna, Austria.
Endocrinology
Cushing's Disease
Continued improvements in hypertension and diabetes during long-term osilodrostat therapy in patients with Cushing’s disease: a pooled analysis from the phase III LINC 3 and LINC 4 studies.
Fleseriu M, Pivonello R, Newell-Price J, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024; Boston, MA.
Long-term effect of subcutaneous pasireotide on clinical and quality-of-life endpoints in patients with Cushing’s disease: results from a non-interventional study.
Bertherat J, Cannavo S, Giordano C, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024, Boston, MA.
A post hoc analysis of the phase IV B2219 study to determine predictive factors for hyperglycemia during treatment with pasireotide.
Samson SL, Bolanowski M, Zhang SL, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
An 8-year interim report of the B2412 study, an open-label, multicenter pasireotide rollover study for patients who continued to receive benefit from pasireotide at completion of an earlier trial.
Gadelha M, Bronstein MD, Grineva E, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Clinical improvements in patients with Cushing’s disease treated with osilodrostat according to urinary and late-night salivary cortisol levels: pooled analysis from LINC 3 and LINC 4.
Biller MK, Fleseriu M, Pivonello R, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Osilodrostat dosing in 229 patients with Cushing’s disease: a pooled analysis of the LINC Program.
Snyder PJ, Biller BMK, Fleseriu M, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Osilodrostat is effective and well tolerated in patients of asian and non-asian origin with Cushing’s disease: a pooled analysis from LINC 3 and LINC 4.
Snyder PJ, Biller BMK, Fleseriu M, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Patient with successful conception during treatment for Cushing's disease: case report.
Iweha C and Castillo M.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Dosing and titration of osilodrostat in a real-world cohort of US patients with endogenous Cushing’s disease: analysis of the ILLUSTRATE study.
Ioachimescu AG, Auchus RJ, Huang W, et al.
Presented at Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Effect of osilodrostat on androgens and adrenal hormones in patients with Cushing’s disease: long-term findings from the phase III prospective LINC 3 study.
Fleseriu M, Biller B, Shimatsu A, et al.
Presented at the Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Improvements in clinical signs of hypercortislism and quality of life according to urinary and late-night salivary cortisol levels in patients with Cushing's disease treated with osilodrostat.
Biller BMK, Pivonello R, Feelders RA, et al.
Presented at Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Osilodrostat provides sustained clinical benefits and improves health-related quality of life in patients with Cushing's disease: results from the phase III LINC 4 study.
Feelders RA, Gadelha M, Bex M, et al.
Presented at Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Change in androgens and adrenal hormones during long-term osilodrostat treatment in patients with Cushing’s disease: results from the phase III, prospective LINC 3 study.
Pivonello R, Biller B, Shimatsu, A, et al.
Presented at European Congress of Endocrinology; May 21-24, 2022; Milan, Italy.
Hypertension and diabetes improvement during osilodrostat therapy in patients with Cushing's disease: analyses from the phase III LINC 3 study.
Fleseriu M, Pivonello R, Newell-Price J, et al.
Presented at 31st AACE Annual Meeting; May 12-14, 2022; San Diego, CA.
Long-term results from the phase III LINC 4 study: osilodrostat maintained normal mean urinary free cortisol in patients with Cushing’s disease, with a favorable safety profile.
Gadelha M, Synder P, Witek P, et al.
Presented at 31st AACE Annual Meeting; May 12-14, 2022; San Diego, CA.
Osilodrostat therapy improves physical features associated with hypercortisolism in patients with Cushing's disease: findings from the phase III LINC 3 study.
Pivonello R, Fleseriu M, Shimatsu A, et al.
Presented at 31st AACE Annual Meeting; May 12-14; 2022; San Diego, CA.
Effect of osilodrostat on clinical signs, physical features and health-related quality of life (HRQoL) by degree of mUFC control in patients with Cushing’s disease (CD): results from the LINC 3 study.
Pivonello R, Fleseriu M, Newell-Price J, et al.
Presented at 30th AACE Annual Meeting; May 26-29, 2021; Jacksonville, FL.
Cushing's Syndrome
A non-interventional, multinational, phase IV study to evaluate the long-term safety and efficacy of osilodrostat in patients with endogenous Cushing’s syndrome (LINC 6): 1-year real-world interim analysis.
Bancos I, Geer E, Castinetti F, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024; Boston, MA.
Effect of osilodrostat on cardiovascular and metabolic manifestations of hypercortisolism in patients with non-pituitary Cushing’s syndrome: findings from a retrospective observational study (LINC 7).
Scheyer N, Bertherat J, Decoudier B, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024; Boston, MA.
Safety and effectiveness of osilodrostat in patients with non-pituitary Cushing’s syndrome: results from the retrospective observational LINC 7 study.
Tabarin A, Bertherat J, Decoudier B, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024; Boston, MA.
Management, safety, and efficacy of osilodrostat treatment in US patients with non-pituitary Cushing's syndrome: results from the ILLUSTRATE study.
Auchus RJ, Fleseriu M, Huang W, et al.
Presented at Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Osilodrostat
Prescribing InformationA non-interventional, multinational, phase IV study to evaluate the long-term safety and efficacy of osilodrostat in patients with endogenous Cushing’s syndrome (LINC 6): 1-year real-world interim analysis.
Bancos I, Geer E, Castinetti F, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024; Boston, MA.
Continued improvements in hypertension and diabetes during long-term osilodrostat therapy in patients with Cushing’s disease: a pooled analysis from the phase III LINC 3 and LINC 4 studies.
Fleseriu M, Pivonello R, Newell-Price J, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024; Boston, MA.
Effect of osilodrostat on cardiovascular and metabolic manifestations of hypercortisolism in patients with non-pituitary Cushing’s syndrome: findings from a retrospective observational study (LINC 7).
Scheyer N, Bertherat J, Decoudier B, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024; Boston, MA.
Safety and effectiveness of osilodrostat in patients with non-pituitary Cushing’s syndrome: results from the retrospective observational LINC 7 study.
Tabarin A, Bertherat J, Decoudier B, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024; Boston, MA.
Clinical improvements in patients with Cushing’s disease treated with osilodrostat according to urinary and late-night salivary cortisol levels: pooled analysis from LINC 3 and LINC 4.
Biller MK, Fleseriu M, Pivonello R, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Osilodrostat dosing in 229 patients with Cushing’s disease: a pooled analysis of the LINC Program.
Snyder PJ, Biller BMK, Fleseriu M, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Osilodrostat is effective and well tolerated in patients of asian and non-asian origin with Cushing’s disease: a pooled analysis from LINC 3 and LINC 4.
Snyder PJ, Biller BMK, Fleseriu M, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Dosing and titration of osilodrostat in a real-world cohort of US patients with endogenous Cushing’s disease: analysis of the ILLUSTRATE study.
Ioachimescu AG, Auchus RJ, Huang W, et al.
Presented at Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Effect of osilodrostat on androgens and adrenal hormones in patients with Cushing’s disease: long-term findings from the phase III prospective LINC 3 study.
Fleseriu M, Biller B, Shimatsu A, et al.
Presented at the Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Improvements in clinical signs of hypercortislism and quality of life according to urinary and late-night salivary cortisol levels in patients with Cushing's disease treated with osilodrostat.
Biller BMK, Pivonello R, Feelders RA, et al.
Presented at Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Management, safety, and efficacy of osilodrostat treatment in US patients with non-pituitary Cushing's syndrome: results from the ILLUSTRATE study.
Auchus RJ, Fleseriu M, Huang W, et al.
Presented at Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Osilodrostat provides sustained clinical benefits and improves health-related quality of life in patients with Cushing's disease: results from the phase III LINC 4 study.
Feelders RA, Gadelha M, Bex M, et al.
Presented at Endocrine Society Annual Meeting; June 11-14, 2022; Atlanta, GA.
Change in androgens and adrenal hormones during long-term osilodrostat treatment in patients with Cushing’s disease: results from the phase III, prospective LINC 3 study.
Pivonello R, Biller B, Shimatsu, A, et al.
Presented at European Congress of Endocrinology; May 21-24, 2022; Milan, Italy.
Hypertension and diabetes improvement during osilodrostat therapy in patients with Cushing's disease: analyses from the phase III LINC 3 study.
Fleseriu M, Pivonello R, Newell-Price J, et al.
Presented at 31st AACE Annual Meeting; May 12-14, 2022; San Diego, CA.
Long-term results from the phase III LINC 4 study: osilodrostat maintained normal mean urinary free cortisol in patients with Cushing’s disease, with a favorable safety profile.
Gadelha M, Synder P, Witek P, et al.
Presented at 31st AACE Annual Meeting; May 12-14, 2022; San Diego, CA.
Osilodrostat therapy improves physical features associated with hypercortisolism in patients with Cushing's disease: findings from the phase III LINC 3 study.
Pivonello R, Fleseriu M, Shimatsu A, et al.
Presented at 31st AACE Annual Meeting; May 12-14; 2022; San Diego, CA.
Effect of osilodrostat on clinical signs, physical features and health-related quality of life (HRQoL) by degree of mUFC control in patients with Cushing’s disease (CD): results from the LINC 3 study.
Pivonello R, Fleseriu M, Newell-Price J, et al.
Presented at 30th AACE Annual Meeting; May 26-29, 2021; Jacksonville, FL.
Pasireotide for injectable suspension
Prescribing InformationA post hoc analysis of the phase IV B2219 study to determine predictive factors for hyperglycemia during treatment with pasireotide.
Samson SL, Bolanowski M, Zhang SL, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
An 8-year interim report of the B2412 study, an open-label, multicenter pasireotide rollover study for patients who continued to receive benefit from pasireotide at completion of an earlier trial.
Gadelha M, Bronstein MD, Grineva E, et al.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Patient with successful conception during treatment for Cushing's disease: case report.
Iweha C and Castillo M.
Presented at Endocrine Society Annual Meeting; June 15-18, 2023; Chicago, IL.
Pasireotide injection
Prescribing InformationLong-term effect of subcutaneous pasireotide on clinical and quality-of-life endpoints in patients with Cushing’s disease: results from a non-interventional study.
Bertherat J, Cannavo S, Giordano C, et al.
Presented at Endocrine Society Annual Meeting; June 1-4, 2024, Boston, MA.
Medical Education
Clinical Trials
Clinical trials are essential for developing safe and effective treatment for our patients. Our goal is to broaden efforts in the rare disease space, striving to improve our products.
